Wealthcare Advisory Partners LLC raised its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 14,136.6% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 28,758 shares of the biopharmaceutical company’s stock after acquiring an additional 28,556 shares during the period. Bristol-Myers Squibb makes up approximately 0.5% of Wealthcare Advisory Partners LLC’s portfolio, making the stock its 26th biggest position. Wealthcare Advisory Partners LLC’s holdings in Bristol-Myers Squibb were worth $1,833,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Bristol-Myers Squibb by 0.3% in the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after purchasing an additional 333,685 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Bristol-Myers Squibb by 2.4% in the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after purchasing an additional 2,367,864 shares in the last quarter. Dodge & Cox lifted its stake in shares of Bristol-Myers Squibb by 1.6% in the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after purchasing an additional 459,271 shares in the last quarter. Jennison Associates LLC lifted its stake in shares of Bristol-Myers Squibb by 16.2% in the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after purchasing an additional 3,735,453 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Bristol-Myers Squibb by 3.9% in the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after purchasing an additional 910,496 shares in the last quarter. Institutional investors own 69.70% of the company’s stock.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 4,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were bought at an average cost of $62.30 per share, with a total value of $249,200.00. Following the transaction, the director now directly owns 22,000 shares in the company, valued at approximately $1,370,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the transaction, the executive vice president now directly owns 9,251 shares in the company, valued at $585,033.24. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

Several equities analysts have recently weighed in on the company. Citigroup set a $72.00 price objective on Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Thursday, October 26th. Vetr lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price objective on the stock. in a research note on Friday, December 22nd. Zacks Investment Research lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Monday, January 29th. Finally, Credit Suisse Group set a $62.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $65.58.

Bristol-Myers Squibb Co (NYSE BMY) opened at $62.63 on Thursday. Bristol-Myers Squibb Co has a 52-week low of $51.12 and a 52-week high of $66.10. The company has a market capitalization of $99,675.04, a P/E ratio of 106.15, a P/E/G ratio of 1.92 and a beta of 1.09. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 33.68% and a net margin of 4.85%. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the company posted $0.63 EPS. Bristol-Myers Squibb’s quarterly revenue was up 3.9% on a year-over-year basis. analysts predict that Bristol-Myers Squibb Co will post 3.17 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.55%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date was Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 271.19%.

COPYRIGHT VIOLATION NOTICE: “Bristol-Myers Squibb Co (BMY) Holdings Increased by Wealthcare Advisory Partners LLC” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/02/08/bristol-myers-squibb-co-bmy-holdings-increased-by-wealthcare-advisory-partners-llc.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.